BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang C, Zeng F, Gao X, Zhao S, Li X, Liu S, Li N, Deng C, Zhang B, Gong R. Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design. J Biol Chem 2019;294:10638-48. [PMID: 31138647 DOI: 10.1074/jbc.RA119.007443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses 2021;13:2106. [PMID: 34696536 DOI: 10.3390/v13102106] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Dai L, Xu K, Li J, Huang Q, Song J, Han Y, Zheng T, Gao P, Lu X, Yang H, Liu K, Xia Q, Wang Q, Chai Y, Qi J, Yan J, Gao GF. Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nat Immunol 2021;22:958-68. [PMID: 34267374 DOI: 10.1038/s41590-021-00966-6] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
3 De Lorenzo G, Tandavanitj R, Doig J, Setthapramote C, Poggianella M, Sanchez-Velazquez R, Scales HE, Edgar JM, Kohl A, Brewer J, Burrone OR, Patel AH. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge. J Virol 2020;95:e01415-20. [PMID: 33028720 DOI: 10.1128/JVI.01415-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wang X, Tai W, Zhang X, Zhou Y, Du L, Shen C. Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. Vaccines (Basel) 2019;7:E161. [PMID: 31717890 DOI: 10.3390/vaccines7040161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]